24th Scientific Symposium of the Austrian Pharmacological Society
Graz, 27–28 September 2018

MEETING ABSTRACT

A2.1
Apolipoprotein A-IV potently suppresses eosinophil responsiveness in vitro and alleviates house dust mite-induced airway hyperreactivity in mice
David ROULA1, Anna THEILER1, Petra LUSCHNIG1, Gunter J. STURM2, Gunther MARSCHE1, Ákos HEINEMANN1 and Eva M. STURM1,*
1Section of Pharmacology, Otto Loewi Research Center, Medical University of Graz, Austria; 2Department of Dermatology and Venereology, Medical University of Graz, Austria

Background: Eosinophil accumulation orchestrated by allergic sensitization and T2-mediated immune response is a hallmark of allergic inflammation as observed in allergic rhinitis and severe asthma. Recent studies pointed out a crucial role for apolipoproteins in the pathogenesis of inflammatory diseases. However, the role of apolipoprotein A-IV (apoA-IV) in allergic inflammation has not been addressed thus far. Here, we explored the signaling mechanism and anti-inflammatory effects of apoA-IV on eosinophil effector function in vitro and in vivo.

Methods: In vitro studies included apoA-IV measurement in serum of healthy and allergic individuals, as well as migratory responsiveness, respiratory burst and calcium mobilization of human peripheral blood eosinophils. Allergen-driven airway inflammation was assessed in a mouse model of acute house dust mite (HDM)-induced asthma.

Results: ApoA-IV levels were significantly decreased in serum from allergic patients compared to healthy controls. Recombinant apoA-IV potently inhibited eosinophil responsiveness by means of shape change, integrin expression and chemotaxis. We were able to elucidate the underlying molecular mechanism, which was independent of ABCAI and SRBI binding but involved Rev-ErbA-α. Moreover, apoA-IV induced the PI3K/PDK1-dependent activation of PKA. Of note, systemic application of apoA-IV clearly prevented AHR and reduced the influx of inflammatory cells into the airways in a murine model of HDM-induced allergic asthma.

Discussion: ApoA-IV is an endogenous anti-inflammatory protein that potently suppresses eosinophil effector function. Here, we provide new insights into the molecular mechanisms underlying the apoA-IV-induced signaling in eosinophils. Our data indicate that exogenously added apoA-IV may represent a novel pharmacological approach for the treatment of allergic inflammation and other eosinophil-driven disorders.

Acknowledgements: A. T. is a recipient of a DOC Fellowship of the Austrian Academy of Sciences at the Otto Loewi Research Center.

*Corresponding author e-mail: eva.sturm@medunigraz.at